Journal September 26, 2026 4 min read

Common misconceptions about long-term potentiation

Long-term potentiation (LTP) is a persistent activity-dependent increase in synaptic strength, widely studied as a cellular correlate of learning and memory. This page addresses common misconceptions about LTP, drawing o

peptides-pro Editorial

What is long-term potentiation?

Long-term potentiation (LTP) is a persistent, activity-dependent increase in synaptic efficacy following brief, high-frequency stimulation. It is a form of synaptic plasticity, often described as a cellular correlate of learning and memory. LTP is not a single entity but a family of phenomena distinguished by induction protocols, expression mechanisms, and brain regions. The term was coined in 1973 by Bliss and Lømo, who observed sustained enhancement of synaptic transmission in the rabbit hippocampus after brief tetanic stimulation of the perforant path. LTP has since been documented at excitatory synapses throughout the mammalian central nervous system, including the hippocampus, cortex, amygdala, and cerebellum. It is not a molecule, a supplement, or a clinical endpoint; it is an experimental measure of synaptic change.

The work centres on glutamatergic synapses, particularly the N-methyl-D-aspartate receptor (NMDAR) family, which serves as a coincidence detector for LTP induction at many synapses. Other receptor families, such as α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) and metabotropic glutamate receptors (mGluRs), contribute to expression and maintenance.

Research Studies

Oxiracetam and cholinergic modulation in cognitive impairment

A narrative review evaluated the mechanistic basis, clinical efficacy, and safety profile of oxiracetam for cognitive dysfunction across neurological disorders [1]. The review synthesised preclinical and clinical literature, noting that oxiracetam's pharmacodynamics include effects on cholinergic systems, which are implicated in LTP. However, the evidence for direct effects on LTP is limited and largely derived from animal models. The review highlighted that existing treatments, such as cholinesterase inhibitors and memantine, provide limited and variable benefits, and that oxiracetam's potential remains investigational [1].

Genistein and oestrogen receptor-mediated LTP protection

Isoflavones, including genistein, are naturally occurring compounds that can activate oestrogen receptors in the brain, providing protection in terms of long-term potentiation as well as antioxidant, anti-inflammatory, and neurotrophic effects (e.g., BDNF upregulation) [3]. A twelve-week clinical trial, GECFAMc, is investigating the effects of genistein and equol on cognitive function and mood [3]. This trial is ongoing; no results are available. The evidence for LTP protection comes from preclinical studies, and it is not established that these effects translate to humans.

L-carnitine and hippocampal synaptic plasticity in Alzheimer's disease models

In a rat model of Alzheimer's disease, chronic L-carnitine attenuated amyloid-beta 1-42 (Aβ₁-₄₂)-induced spatial learning and memory deficits following intracerebroventricular administration [4]. The study reported improvements in hippocampal dysfunction and synaptic plasticity, but these findings are animal-only and do not demonstrate efficacy in humans.

Bacopa monnieri and synaptic plasticity in vascular dementia models

A Bacopa-enriched formulation enhanced memory and synaptic plasticity in a rat model of vascular dementia [5]. The study evaluated multiple pathways, but the results are preclinical and have not been confirmed in human trials.

Polycomb-focused TWAS and neuronal identity in eating disorders

A transcriptome-wide association study (TWAS) identified a neuronal identity, circuit-maintenance, and cellular-logistics architecture linking anorexia nervosa and binge-eating behaviour [2]. The study prioritised synaptic vesicle dynamics, RHOA-centered trafficking, and mitochondrial substrate utilization as candidate interfaces between eating-disorder genetic risk and nicotinamide mononucleotide (NMN)-sensitive biology [2]. While this research does not directly address LTP, it highlights the complexity of synaptic and cellular processes that may intersect with plasticity mechanisms. The findings are associative and require functional validation.

Common misconceptions about LTP

Misconception 1: LTP is a single mechanism. In reality, LTP encompasses multiple forms with distinct induction and expression mechanisms. Misconception 2: LTP is synonymous with memory. LTP is a cellular correlate, not a direct measure of memory; memory involves systems-level processes. Misconception 3: LTP can be reliably enhanced by dietary supplements. Most evidence for LTP modulation comes from animal or in vitro studies, and human data are scarce. Misconception 4: LTP is always beneficial. Excessive LTP can contribute to excitotoxicity and epilepsy. Misconception 5: LTP is permanent. LTP can decay, be reversed (depotentiation), or be metaplastic.

Table: Comparison of LTP findings across models

Compound/Intervention	Model	LTP-related finding	Evidence level
Oxiracetam	Preclinical and clinical (narrative review)	Cholinergic modulation; potential cognitive benefits	Mixed; limited direct LTP evidence [1]
Genistein	Preclinical; ongoing clinical trial	Oestrogen receptor activation; LTP protection	Preclinical; trial ongoing [3]
L-carnitine	Rat model of Alzheimer's disease	Attenuated Aβ₁-₄₂-induced deficits; improved synaptic plasticity	Animal-only [4]
Bacopa-enriched formulation	Rat model of vascular dementia	Enhanced memory and synaptic plasticity	Animal-only [5]

If you are reading this for personal health reasons

The materials and compounds discussed here are sold for laboratory research purposes only. We do not provide dosing, medical guidance, or recommendations for personal use. Anyone considering a compound for themselves should speak to a licensed clinician.